Breaking News, Promotions & Moves

NeuBase Therapeutics Appoints Chief Scientific Officer

Dr. Curt Bradshaw brings decades of experience in successfully delivering genetic medicines to clinics.

By: Contract Pharma

Contract Pharma Staff

NeuBase Therapeutics Inc., a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, has appointed Curt Bradshaw, Ph.D., as its new chief scientific officer.   Dr. Bradshaw is a proven drug developer in the field of precision genetic medicines, coming to NeuBase from his most recent role as chief scientific officer at Arrowhead Pharmaceuticals. In his new role, Bradshaw will be responsible for leading and expanding NeuBase’s PATrOL-enabled anti-gene pi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters